Skip to content

A randomized controlled trial of nutrition with and without corticosteroids in acute severe ulcerative colitis

A pilot study of exclusive enteral nutrition with corticosteroids vs corticosteroids alone in patients with acute severe ulcerative colitis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/06/025989
Enrollment
30
Registered
2020-06-19
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K519- Ulcerative colitis, unspecified

Interventions

Intervention1: Intervention: â?¢ Inj hydrocortisone 100 mg iv 6 hrly. â?¢ Semi-elemental EEN diet as per body weight per-oral or through NG tube Control Intervention1: Control group: Semi-elemental

Sponsors

AIIMS
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients presented with Acute Severe Ulcerative Colitis as defined by Truelove and Wittâ??s criteria. 2.Patients who have not received any dose of steroid or other immune-suppressive therapy for this episode from outside. 3.Patients giving written informed consent

Exclusion criteria

Exclusion criteria: 1. Age 75 years. 2. Patients with indeterminate form of colitis or crohnâ??s colitis. 3. UC patients with infection related flares (like CMV or C. difficile infection) 4. Patients with infective colitis or colitis of other etiologies. 5. ASUC patients having toxic megacolon, paralytic ileus or perforation. 6. Pregnancy 7. Other major co-morbid conditions like acute myocardial infarction, chronic kidney disease or chronic liver disease

Design outcomes

Primary

MeasureTime frame
a) Proportion of patients requiring colectomy in both the groups. b) Proportion of patients requiring medical rescue therapy in both the groups c) Proportion of patients who have complete response and partial response to iv steroid on day 7 of treatment. Timepoint: 7 days

Secondary

MeasureTime frame
a) Changes in fecal calprotectin and serum CRP level after 3rd day of treatment in both the groups. b) Changes in body weight, serum albumin level in both the groups at the end of follow up (Day 7) c) Treatment related adverse events in both the group. Timepoint: 7 days

Countries

India

Contacts

Public ContactDr Pabitra Sahu

AIIMS

dr.saurabhkedia@yahoo.com9868428535

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 16, 2026